The first EU Joint Clinical Assessments (JCAs) are now providing real-world evidence of how the new ...
Read moreThe publication of the first three EU Joint Clinical Assessments (JCAs) provides the first opportuni...
Read moreIntroduction An EU-focused PICOS (population, intervention, comparator, outcomes or study-type) fram...
Read moreExecutive Summary Rare disease assessments rely on specialist clinical and patient expertise to inte...
Read moreAs NICE and EU Joint Clinical Assessment (JCA) requirements increasingly need to be considered in pa...
Read moreThe first EU Joint Clinical Assessment (JCA) has now been published, providing the first practical i...
Read moreExpert contributions are critical to health technology assessment (HTA), particularly in rare diseas...
Read moreThe HTA Coordination Group (HTACG) has now confirmed the 2026 request periods for joint scientific c...
Read moreObjectives: EUHTA regulation has applied from the 1st January 2025 for oncology pr...
Read moreObjectives: To analyse how the mandatory EU Joint Clinical Assessment (JCA) could in...
Read more